Literature DB >> 2114093

Hormonal regulation of Gi2 alpha-subunit phosphorylation in intact hepatocytes.

M Bushfield1, G J Murphy, B E Lavan, P J Parker, V J Hruby, G Milligan, M D Houslay.   

Abstract

Hepatocytes contain the Gi2 and Gi3 forms of the 'Gi-family' of guanine-nucleotide-binding proteins (G-proteins), but not Gi1. The anti-peptide antisera AS7 and I3B were shown to immunoprecipitate Gi2 and Gi3 selectively, and the antiserum CS1 immunoprecipitated the stimulatory G-protein Gs. Treatment of intact, 32P-labelled hepatocytes with one of glucagon, TH-glucagon ([1-N-alpha-trinitrophenylhistidine, 12-homoarginine]glucagon), Arg-vasopressin, angiotensin-II, the phorbol ester TPA (12-O-tetradecanoylphorbol 13-acetate) and 8-bromo-cyclic AMP elicited a time- and dose-dependent increase in the labelling of the alpha-subunit of immunoprecipitated Gi2 which paralleled the loss of ability of low concentrations of the non-hydrolysable GTP analogue guanosine 5'-[beta gamma-imido]triphosphate (p[NH]ppG) to inhibit forskolin-stimulated adenylate cyclase activity ('Gi'-function). The immunoprecipitation of phosphorylated Gi-2 alpha-subunit by the antiserum AS7 was blocked in a dose-dependent fashion by the inclusion of the C-terminal decapeptide of transducin, but not that of Gz (a 'Gi-like' G-protein which lacks the C-terminal cysteine group which is ADP-ribosylated by pertussis toxin in other members of the Gi family), in the immunoprecipitation assay. No labelling of the alpha-subunits of either Gi3 or Gs was observed. alpha-Gi2 was labelled in the basal state and this did not change over 15 min in the absence of ligand addition. In contrast to the monophasic dose-effect curves seen with vasopressin, angiotensin and TPA, the dose-effect curve for the glucagon-mediated increase in the labelling of alpha-Gi2 was markedly biphasic where the loss of Gi function paralleled the high-affinity component of the labelling of alpha-Gi2 caused by glucagon. TPA, TH-glucagon, angiotensin-II and vasopressin achieved similar maximal increases in the labelling of alpha-Gi2, which was approximately half that found after treatment of hepatocytes with either high glucagon concentrations (1 microM) or 8-bromocyclic AMP. Analysis of the phosphoamino acid content of immunoprecipitated alpha-Gi2 showed the presence of phosphoserine only. Incubation of hepatocyte membranes with [gamma-32P]ATP and purified protein kinase C, but not protein kinase A, led to the incorporation of label into immunoprecipitated alpha-Gi2. This labelling was abolished if membranes were obtained from cells which had received prior treatment with ligands shown to cause the phosphorylation of alpha-Gi2 in intact cells. We suggest that there are two possible sites for the phosphorylation of alpha-Gi2; one for C-kinase and the other for an unidentified kinase whose action is triggered by A-kinase activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114093      PMCID: PMC1131453          DOI: 10.1042/bj2680449

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Studies on the hepatic calcium-mobilizing activity of aluminum fluoride and glucagon. Modulation by cAMP and phorbol myristate acetate.

Authors:  P F Blackmore; J H Exton
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

2.  Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase.

Authors:  T Katada; A G Gilman; Y Watanabe; S Bauer; K H Jakobs
Journal:  Eur J Biochem       Date:  1985-09-02

3.  Krebs EG: Purification and characterization of a protein inhibitor of adenosine 3',5'-monophosphate-dependent protein kinases.

Authors:  D A Walsh; C D Ashby; C Gonzalez; D Calkins; E H Fischer
Journal:  J Biol Chem       Date:  1971-04-10       Impact factor: 5.157

4.  Cholera toxin mediated activation of adenylate cyclase in intact rat hepatocytes.

Authors:  M D Houslay; K R Elliott
Journal:  FEBS Lett       Date:  1979-08-15       Impact factor: 4.124

5.  The glucagon receptor of rat liver plasma membrane can couple to adenylate cyclase without activating it.

Authors:  M D Houslay; J C Metcalfe; G B Warren; T R Hesketh; G A Smith
Journal:  Biochim Biophys Acta       Date:  1976-06-17

6.  Activation of two signal-transduction systems in hepatocytes by glucagon.

Authors:  M J Wakelam; G J Murphy; V J Hruby; M D Houslay
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

7.  Differential effects of tryptophan on glucose synthesis in rats and guinea pigs.

Authors:  S A Smith; K R Elliott; C I Pogson
Journal:  Biochem J       Date:  1978-12-15       Impact factor: 3.857

8.  Glucagon amino groups. Evaluation of modifications leading to antagonism and agonism.

Authors:  M D Bregman; D Trivedi; V J Hruby
Journal:  J Biol Chem       Date:  1980-12-25       Impact factor: 5.157

9.  Forskolin and ethanol both perturb the structure of liver plasma membranes and activate adenylate cyclase activity.

Authors:  A D Whetton; L Needham; N J Dodd; C M Heyworth; M D Houslay
Journal:  Biochem Pharmacol       Date:  1983-05-15       Impact factor: 5.858

10.  Stimulation of 1,2-diacylglycerol accumulation in hepatocytes by vasopressin, epinephrine, and angiotensin II.

Authors:  S B Bocckino; P F Blackmore; J H Exton
Journal:  J Biol Chem       Date:  1985-11-15       Impact factor: 5.157

View more
  29 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Gi3 does not contribute to the inhibition of adenylate cyclase when stimulation of an alpha 2-adrenergic receptor causes activation of both Gi2 and Gi3.

Authors:  S J McClue; E Selzer; M Freissmuth; G Milligan
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

3.  Phosphorylation of the spliced variant forms of the recombinant stimulatory guanine-nucleotide-binding regulatory protein (Gs alpha) by protein kinase C.

Authors:  N J Pyne; M Freissmuth; S Palmer
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

4.  Alterations in G-protein expression and the hormonal regulation of adenylate cyclase in the adipocytes of obese (fa/fa) Zucker rats.

Authors:  D Strassheim; T Palmer; G Milligan; M D Houslay
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

5.  A role for protein kinase C-mediated phosphorylation in eliciting glucagon desensitization in rat hepatocytes.

Authors:  A Savage; L Zeng; M D Houslay
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

6.  Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways.

Authors:  C Klingler; N Ancellin; M B Barrault; A Morel; B Corman
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

7.  The cross-regulation of Gi-protein by cholera toxin involves a phosphorylation by protein kinase A.

Authors:  R Levistre; M Berguerand; G Bereziat; J Masliah
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

8.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Authors:  Y Shakur; M Wilson; L Pooley; M Lobban; S L Griffiths; A M Campbell; J Beattie; C Daly; M D Houslay
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

9.  The role of Gi and the membrane-fluidizing agent benzyl alcohol in modulating the hysteretic activation of human platelet adenylate cyclase by guanylyl 5'-imidodiphosphate.

Authors:  S Spence; M D Houslay
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

10.  Receptor class desensitization of leukocyte chemoattractant receptors.

Authors:  J R Didsbury; R J Uhing; E Tomhave; C Gerard; N Gerard; R Snyderman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.